Synergistic Antiplatelet Effect of Ridogrel, a Combined Thromboxane Receptor Antagonist and Thromboxane Synthase Inhibitor, and UDCG-212, a cAMP-Phosphodiesterase Inhibitor

Summary

Ridogrel, a combined thromboxane receptor antagonist and thromboxane synthase inhibitor (1), inhibits platelet aggregation. Following stimulation with arachidonic acid, cAMP-levels are increased in human platelets preincubated with ridogrel, this is due to the known reorientation of the metabolism of the formed endoperoxides towards adenylate cyclase stimulating prostaglandins.

Pretreatment of resting platelets with UDCG-212, a cAMP-phosphodiesterase inhibitor (2), also inhibits platelet aggregation induced by arachidonic acid, concomitant with an increase in cAMP levels, due to an inhibition of its breakdown. Under basal conditions, cAMP also is increased.

By combining the two drugs, a more than additive action was observed on platelet aggregation and on both resting and stimulated platelet cAMP content. The appropriate combination may result in a more effective antiplatelet strategy.

• References

• 1 Hoet B, Falcon C, De ReysS, Arnout J, Deckmyn H, Vermylen J. R68070, a combined thromboxane/endoperoxide receptor antagonist and thromboxane synthase inhibitor, inhibits human platelet activation in vitro and in vivo: a comparison with aspirin. Blood 1990; 75: 646-653
• 2 Berger G, Meyer W, Scholz H, Starbaty J. Effects of the benzimidazole derivatives pinmobendan and 2-(4-hydroxy-phenyl)-5-(5-methyl-3-OXO-4-dihydro-2H-6-pyridarinyl)benzimidazol HC1 on phosphodiesterase activity and force of contraction of guinea pig hearts. Arzneim Forsch 1985; 35: 1668-1673
• 3 Hamberg MJ, Svensson J, Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci USA 1975; 72: 2994-2998
• 4 Brass LF, Shaller CC, Belmonte EJ. Inositol 1,4,5-trisphosphate induced granule secretion in platelets. Evidence that the activation of phospholipase C mediated by platelet thromboxane receptors involves a guanine nucleotide binding protein-dependent mechanism distinct from that of thrombin. J Clin Invest 1987; 79: 1269-1275
• 5 Rybicki JP, Le BretonGC. Prostaglandin H2 directly lowers human platelet cAMP levels Thromb Res 1983; 30: 407-414
• 6 Avdonin PV, Svitina-Ulutina IV, Ley tinVL, Thachuk VA. Interaction of stable prostaglandin endoperoxide analogs U46619 and U44069 with human platelet membranes: coupling of receptors with high-affinity GTPase and adenylate cyclase. Thromb Res 1985; 40: 101-112
• 7 Gresele P, Arnout J, Deckmyn H, Huybrechts E, Pieters G, Vermylen J. Role of proaggregatory and antiaggregatory prostaglandins in hemostasis. Studies with combined thromboxane synthase inhibition and thromboxane receptor antagonism. J Clin Invest 1987; 80: 1435-1445
• 8 Brass LF, Woolkalis MJ, Manning DR. Interactions in platelets between G-proteins and the agonists that stimulate phospholipase C and inhibit adenylyl cyclase. J Biol Chem 1988; 263: 5348-5355
• 9 Vermylen J, Defreyn G, Carreras LO, Machin SJ, Van SchaerenJ, Verstraete M. Thromboxane synthetase inhibition as antithrombotic strategy. Lancet 1981; i: 1073-1075
• 10 Gresele P, Deckmyn H, Huybrechts E, Vermylen J. Serum albumin enhances the impairment of platelet aggregation with thromboxane synthase inhibition by increasing the formation of prostaglandin D₂ . Biochem Pharmacol 1984; 33: 2083-2088
• 11 Mills DCB, MacFarlane DE. Stimulation of human platelet adenylate cyclase by prostaglandin D₂ . Thromb Res 1974; 5: 401-412
• 12 Heptinstall S, Bevan J, Cockbill SR, Hanley SP, Parry MJ. Effect of a selective inhibitor of thromboxane synthetase on human blood platelet behaviour. Thromb Res 1980; 20: 219-230
• 13 Bertele V, Cerletti C, Schieppati A, Di MinnoG, de GaetanoG. Inhibition of thromboxane synthetase does not necessarily prevent platelet aggregation. Lancet 1981; i: 1057-1058
• 14 FitzGerald GA, Reilly IA, Pedersen AK. The biochemical pharmacology of thromboxane synthase inhibition in man. Circulation 1985; 72: 1194-1201
• 15 Sills T, Heptinstall S. Effects of a thromboxane synthetase inhibitor and a cAMP phosphodiesterase inhibitor, singly and in combination, on platelet behaviour. Thromb Haemostas 1986; 55: 305-308
• 16 Gresele P, Deckmyn H, Amout J, Lemmens J, Janssens W, Vermylen J. BM 13.177, a selective blocker of platelet and vessel wall thromboxane receptors, is active in man. Lancet 1984; i: 991-994
• 17 Bertele V, de GaetanoG. Potentiation by dazoxiben, a thromboxane synthetase inhibitor, of platelet aggregation inhibitory activity of a thromboxane receptor antagonist and of prostacyclin. Eur J Pharmacol 1982; 85: 331-333
• 18 Gresele P, Deckmyn H, Amout J, Nenci GG, Vermylen J. Characterization of N, N’-bis(3-picolyl)-4-methoxy-isophtalamide (picotamide) as a dual thromboxane synthase inhibitor/thromboxane A₂ receptor antagonist in human platelets. Thromb Haemostas 1989; 61: 479-484
• 19 De ClerckF, Beetens J, de Chaffoy de Courcelles D, Freyne E, Janssen P. R68070: Thromboxane A₂ synthase inhibition and thromboxane A₂/prostaglandin endoperoxide receptor blockade, combined in one molecule I. Biochemical profile in vitro. Thromb Haemostas 1989; 61: 35-42
• 20 Bom GVR, Cross MJ. The aggregation of blood platelets. J Physiol 1963; 168: 178
• 21 Krishna G, Weiss B, Brodie BB. A simple, sensitive method for the assay of adenylyl cyclase. J Pharmacol Exp Ther 1968; 163: 379-385
• 22 Salzman EW, Neri LL. Cyclic 3’,5’-adenosine monophosphate in human blood platelets. Nature 1969; 224: 609-610
• 23 Berenbaum MC. The expected effect of a combination of agents: the general solution. J Theoret Biol 1985; 114: 413-431
• 24 Haslam RJ, Davidson MML, Davies T, Lynham JA, McClenaghan MD. Regulation of blood platelet function by cyclic nucleotides. Adv Cyclic Nucl Res 1978; 9: 533-552
• 25 Defreyn G, Deckmyn H, Vermylen J. A thromboxane synthetase inhibitor reorients endoperoxide metabolism in whole blood towards prostacyclin and prostaglandin E₂ . Thromb Res 1982; 26: 389-400
• 26 Deckmyn H, Van HoutteE, Verstraete M, Vermylen J. Manipulation of the local thromboxane and prostacyclin balance in vivo by the antithrombotic compounds dazoxiben, acetylsalicylic acid and nafazatrom. Biochem Pharmacol 1983; 32: 2757-2767
• 27 Gresele P, Blockmans D, Deckmyn H, Vermylen J. Adenylate cyclase activation determines the effect of thromboxane synthase inhibitors on platelet aggregation in vitro. Comparison of platelets from responders and nonresponders. J Pharmacol Exp Ther 1988; 246: 301-307
• 28 Smith JB. Effect of thromboxane synthetase inhibitors on platelet function: enhancement by inhibition of phosphodiesterase Thromb Res 1982; 28: 477-485
• 29 Martinez GR, Walker KAM, Hirschfeld DR, Bruno U, Yang DS, Maloney PJ. 3,4-Dihydroquinolin-2(1H)-ones as combined inhibitors of thromboxane A₂ synthase and cAMP-phosphodiesterase. J Medicin Chem 1992; 35: 620-628
• 30 Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, Debianco R, Zeldis SM, Hendrix GH, Bommer WJ, Elkayam U, Kukin ML. Effect of oral milrinone on mortality in severe chronic heart failure. The promise research group. N Engl J Med 1991; 325: 1468-1475
• 31 Gresele P, Deckmyn H, Nenci GG, Vermylen J. Thromboxane synthase inhibitors, thromboxane receptor antagonists and dual blockers in thrombotic disorders. Trend Pharmacol Sci 1991; 12: 158-163
• 32 De ClerckF, Van GorpL, Beetens J, Verheyen A, Janssen PAJ. Arachidonic acid metabolites, ADP and thrombin modulate occlusive thrombus formation over extensive arterial injury in the rat. Blood Coag Fibrinol 1990; 1: 247-258